On the 23rd-24th of May the biggest and the most important meeting for biotechnology industry in Central Europe was held in Brno in Czech Republic. The event was meant to gather scientists, businessmen, journalists, students and all those who are simply interested in this matter. The representatives ...
Read more
EFPIA, the voice of the research-based pharmaceutical industry in Europe, welcomes the launch today by the Innovative Medicines Initiative (IMI) public-private partnership, a €223,7 million programme to tackle antimicrobial resistance and to speed up the development of new antibiotics....
Read more
Mabion co. – Polish company specialized in medical biotechnology; created to implement research and biosimilar drugs – has recently singed a letter of intent with Sothema Laboratories, company from Marocco, in terms of distribution of the MabionCD20 pharmaceutical in the Maghreb countries (Marocco, A...
Read more
We have approached another medical breakthrough: EU has approved the latest Novartis drug – Signifor® – the first pharmaceutical to treat patients with Cushing’s disease. ...
Read more
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 31 national associations and 35 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 2,000 companies committed ...
Read more
Nowadays commercialization of scientific knowledge becomes a new branch of industry. Scientists are more and more conscious that their hard-earned intellectual property, besides fame in scientific world could be a source of money and a starting base for innovative business....
Read more
Life Sciences Employers are becoming more militant in the battle for talents. It is not only about sourcing the right professionals from the market but most of all creating the work environment to attract and retain them....
Read more
Molecular diagnostics assess biological makeup at the genetic level. Unlocking DNA code can reveal variations between individuals which may represent a predisposition to develop a disease or even treatment options that may be more effective in some people. To be precise it could be said that molecul...
Read more
Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD 1.525 billion in an all-cash transaction....
Read more
The Danish biotechnology sector has been developed over more than 100 years and long time ago it reached an undisputed high quality level. Despite the financial crisis the Danish biotech sector has the necessary strength to maintain and develop this high quality level in the future...
Read more
On May 23rd-24th the biggest and the most important meeting for biotechnology industry of Central Europe will be held in Brno in Czech Republic. The event is meant to gather scientists, businessmen, journalists, students and all those who are simply interested in this matter. The representatives of t...
Read more
Despite the dramatic growth in the number and power of molecular diagnostic technologies, the increasing clinical and economic value of the tests derived from them, and the therapeutic power of the drugs whose use can and should be guided by those tests, the reimbursement system for diagnostic tests ...
Read more
Newly developed drugs must be controlled in terms of efficiency and safety. At this step clinical trials are inevitable. They account for the biggest and also the longest part of total cost connected with introduction of new pharmaceuticals to the market. It is estimated that the global market of cli...
Read more